The Milk, Growth and Microbiota Study (MGM)
Primary Purpose
Preterm Infant, Growth Delay, Microbial Colonization
Status
Suspended
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Donor milk
Preterm infant formula
Sponsored by
About this trial
This is an interventional prevention trial for Preterm Infant
Eligibility Criteria
Inclusion Criteria:
- Late preterm newborns >=34 weeks and <37 weeks gestation
- Breastfeeding
- Clinical team plans to start supplementation
Exclusion Criteria:
- Mothers are producing copious breast milk
- Birth weight <2100gm
- Any maternal or infant contraindication to breastfeeding
Sites / Locations
- University of California, San Francisco Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Donor milk
Preterm infant formula
Arm Description
Pasteurized donor breast milk
Preterm formula determined by clinical practice
Outcomes
Primary Outcome Measures
Weight change
Grams
Secondary Outcome Measures
Bifidobacteria
Abundance
Lactobacillus
Abundance
Clostridium
Abundance
Weight change
Grams
Weight change
Grams
Full Information
NCT ID
NCT03220282
First Posted
July 7, 2017
Last Updated
February 2, 2023
Sponsor
University of California, San Francisco
Collaborators
University of California, Davis
1. Study Identification
Unique Protocol Identification Number
NCT03220282
Brief Title
The Milk, Growth and Microbiota Study
Acronym
MGM
Official Title
Milk, Growth and Microbiota: A Randomized, Controlled Trial (RCT) of Donor Milk vs. Formula to Supplement Breastfeeding Late Preterm Newborns
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Suspended
Why Stopped
Difficulty enrolling due to COVID-related restrictions.
Study Start Date
October 30, 2017 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University of California, Davis
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Late preterm infants, who are born at 34, 35 or 36 weeks gestation, often have difficulty feeding, establishing growth, and fighting off infection. Breastfeeding provides improved nutrition to help fight infection, in part because breast milk encourages the growth of healthy bacteria (microbiota) in the infant's intestine. However, when mothers give birth preterm, their breasts are usually not quite ready to make milk; it can take several days to have enough breast milk to match a baby's nutritional needs. If there is not yet enough breast milk, formula is often used. However, formula can interfere with the growth of healthy intestinal bacteria. An alternate nutritional option is donor milk from a certified milk bank, which is available in all neonatal intensive care units (NICUs) in San Francisco. However, no scientific studies have yet studied donor milk for late preterm infants, so currently all San Francisco NICUs (as well as the large majority of NICUs nationwide) reserve donor milk for infants born at <34 weeks. This study's investigators therefore propose the "Milk, Growth and Microbiota (MGM) Study," a randomized controlled trial to compare banked donor milk to formula for breastfeeding late preterm infants born in San Francisco. Once enrolled in MGM, infants will be randomly assigned to receive either formula or banked donor milk if they need additional nutrition until their mothers are making enough milk. After enrolling the babies, investigators will weigh them daily to assess their growth. The investigators will also collect infant bowel movements at baseline, 1 week and 1 month to determine whether donor milk vs. formula impacts the type of bacteria in the baby's intestine. If the study's results show that donor milk optimizes growth while helping establish healthy bacteria in the baby's intestine, donor milk might be postnatal strategy to bolster neonatal nutrition for late preterm infants.
Detailed Description
In the U.S., 8% of all births occur between 34 0/7 and 36 6/7 weeks gestation and are regarded as late preterm birth. Compared to term newborns, late preterm newborns have a much higher risk of morbidity and mortality, in part because of difficulty establishing feeding and growth. Breastfeeding optimizes the nutrition of these infants by supporting growth and establishing a healthy intestinal microbiota. However, maternal breast milk production is often delayed after preterm birth, which can hamper optimal growth. When this occurs, clinicians may use formula to supplement breastfeeding. However, formula alters neonatal intestinal microbiota and can impede some of the benefits of a human milk diet. Donor milk from a certified milk bank could possibly be used instead of formula for supplementation prior to the onset of copious maternal milk production. However, the use of banked donor milk has never been studied in late preterm infants. The aim of this proposal is to report the effects of banked donor milk vs. formula on growth and on intestinal microbiota among late preterm, breastfeeding newborns who require additional nutrition before copious maternal milk is available. This study's investigators therefore propose a randomized, controlled trial enrolling late preterm newborns. Newborns will be randomly assigned either to breastfeed with additional formula feedings, or to breastfeed with additional donor milk feedings. The study's outcomes will be: (1) growth (rate of weight change), and (2) intestinal microbiota. If the study finds that temporary use of donor milk supports growth and maintains healthy intestinal microbiota until copious maternal milk becomes available, temporary use of donor milk might be a postnatal strategy to bolster neonatal nutrition and optimize nutritional support and growth for late preterm infants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Infant, Growth Delay, Microbial Colonization, Breastfeeding, Breast Milk Substitute Intolerance
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial with 2 arms
Masking
Outcomes Assessor
Masking Description
Participant, PI, enrolling nurse and clinical care team will not be blinded as to treatment assignment. Outcomes will be assessed by blinded investigators.
Allocation
Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Donor milk
Arm Type
Active Comparator
Arm Description
Pasteurized donor breast milk
Arm Title
Preterm infant formula
Arm Type
Placebo Comparator
Arm Description
Preterm formula determined by clinical practice
Intervention Type
Other
Intervention Name(s)
Donor milk
Other Intervention Name(s)
Donor breast milk
Intervention Description
For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
Intervention Type
Other
Intervention Name(s)
Preterm infant formula
Other Intervention Name(s)
Formula
Intervention Description
Preterm formula determined by clinical practice
Primary Outcome Measure Information:
Title
Weight change
Description
Grams
Time Frame
Between enrollment and 24 hours after enrollment
Secondary Outcome Measure Information:
Title
Bifidobacteria
Description
Abundance
Time Frame
1 week and 1 month after enrollment
Title
Lactobacillus
Description
Abundance
Time Frame
1 week and 1 month after enrollment
Title
Clostridium
Description
Abundance
Time Frame
1 week and 1 month after enrollment
Title
Weight change
Description
Grams
Time Frame
Between enrollment and 48 hours after enrollment
Title
Weight change
Description
Grams
Time Frame
Between enrollment and 7 days of age
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Hour
Maximum Age & Unit of Time
96 Hours
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Late preterm newborns >=34 weeks and <37 weeks gestation
Breastfeeding
Clinical team plans to start supplementation
Exclusion Criteria:
Mothers are producing copious breast milk
Birth weight <2100gm
Any maternal or infant contraindication to breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerie Flaherman, MD, MPH
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94122
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
The final data set will include information on infant weight and intestinal microbiota, as well as data on other clinical and demographic variables. Once the study has concluded and the data has been de-identified, the investigators will share the de-identified data with other users who agree to a data sharing plan that limits use of the data to research purposes only, excludes any use of the data to identify individual participants and destroys the data once the proposed research has been completed.
Learn more about this trial
The Milk, Growth and Microbiota Study
We'll reach out to this number within 24 hrs